Treatment Options in ErbB2 (HER2)-Positive Breast Cancer - Karger PublishersThis issue is a dedicated supplement published in addition to the regular issues of 'Breast Care' focussing on one specific topic. 'Breast Care' is a well-respected, international peer-reviewed journal in Gynecology. ...
HER2-directed therapy: current treatment options for HER2-positive breast cancer Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imagin... S Ahmed,A Sami,J Xiang - 《Breast Cancer》 被引量: 74...
EP: 12.Treatment Options for HER2+, ER+ Metastatic Breast Cancer EP: 13.Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer Vijayakrishna Gadi, MD, PhD: I’m going to go with that a little further. So Nancy, when you think about hormone-positive, HER2-positive disease, so maybe...
[2] Miglietta F, Bottosso M, Griguolo G, et al. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO open 2022;7:100409. doi:10. 1016/j.esmoop.2022.100409 [3] M. Piccart...
15 Krop explained that this means once the drug enters a HER2-positive cell, the payload—deruxtecan—can separate from trastuzumab and “diffuse out of the cell and hit neighboring cells,” some of which may express low or even normal levels of HER2.15 He proposed that the “...
在中国,乳腺癌已成为女性恶性肿瘤中的头号杀手,而超过 90% 的女性在首次诊断时处于疾病早期 [1] 。在早期乳腺癌患者中,HR+/HER2-型占据了绝大多数。在早期 HR+/HER2-乳腺癌的治疗中,辅助内分泌治疗已经显著改善了患者的预后,并提高了他们的生存率。尽管取得了这样的进展,大约 20% 至 30% 的早期乳腺癌患者...
A video from Virginia Borges (as part of University of Colorado Cancer Center), posted on Apr 14, 2023.
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer Ruicheng Wei Wenli Zhang Yongqiang Shan Journal of Translational Medicine (2024) Tris...
受体酪氨酸激酶成红细胞原癌基因B2(ERBB2),也称为人表皮生长因子受体2(HER2),是一种致癌驱动基因,已成功应用在乳腺癌和胃癌的靶向治疗中。最近,下一代测序(NGS)发现ERBB2是转移性结直肠癌(mCRC)的一个有前景的治疗靶点,有 3-5% 的患者检出HER2变异,但目前还没有批准用于此用途的治疗方法。本文介绍了NGS检测...
Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer. Sara A. Hurvitz, MD The year 2020 saw a myriad of promising studies that resulted in several FDA-approved options for patients wit...